Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses (2021 - 2025)

Historic Other Operating Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $35065.0.

  • InMed Pharmaceuticals' Other Operating Expenses fell 6048.84% to $35065.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $225938.0, marking a year-over-year increase of 4216.55%. This contributed to the annual value of $191106.0 for FY2025, which is 16698.61% up from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Other Operating Expenses stood at $35065.0, which was down 6048.84% from $110196.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Other Operating Expenses registered a high of $145839.0 during Q3 2022, and its lowest value of -$8.8 million during Q2 2022.
  • In the last 5 years, InMed Pharmaceuticals' Other Operating Expenses had a median value of $25107.5 in 2021 and averaged -$872557.2.
  • Examining YoY changes over the last 5 years, InMed Pharmaceuticals' Other Operating Expenses showed a top increase of 44838.82% in 2024 and a maximum decrease of 13360.27% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Other Operating Expenses stood at -$4.2 million in 2021, then surged by 99.45% to -$23286.0 in 2022, then fell by 24.71% to -$29040.0 in 2023, then surged by 405.6% to $88746.0 in 2024, then crashed by 60.49% to $35065.0 in 2025.
  • Its last three reported values are $35065.0 in Q4 2025, $110196.0 for Q3 2025, and $18409.0 during Q2 2025.